Mark Obermann results 3
· Newest (Page 1/1, per page 25)
Author: Mark Obermann ×Clear All Filters
Search Results
Erenumab escalation in migraine - double dose without additional benefit - a retrospective experienceNARA Subscribed
Background Erenumab is a monoclonal antibody specifically targeting the CGRP-receptor. Several studies showed efficacy and safety in patients with migraine. Less is known regarding dosage increase, especially in a difficult to treat patients. The aim of the study is to evaluate the increased dosage under real world conditions with particular focus on 70 mg non-responders. Methods In a retrospective analysis, patients treated i...
Previous1Next